Washington, DC (PRWEB) April 23, 2009
Cardiocore, a premier centralized cardiac safety testing laboratory, announced today that award winning cardiac research expert Rick Turner, PhD, PGCE, MICR, CSci has joined its scientific consulting team. Professor Turner is an internationally recognized authority in the integration of cardiac safety assessment throughout lifecycle drug development, from molecular biology to post-marketing surveillance. His seven books and 100 journal articles comprise a uniquely comprehensive body of cardiac safety research spanning all major testing modalities--electrocardiography (ECG), Holter monitoring, echocardiography (ECHO), multigated acquisition scanning (MUGA), impedance cardiography, and ambulatory blood pressure monitoring (ABPM).
In his role as Cardiocore Senior Scientist, Professor Turner will assist clinical trial sponsors with strategic planning, protocol development, expert reporting, and regulatory submissions. Having served as a Principal Clinical Submissions Scientist for GlaxoSmithKline, he holds first-hand knowledge of the internal processes and regulatory submission challenges faced by clinical trial sponsors. This important shared experience underpins Professor Turner's collaboration with drug researchers, helping them to optimize the regulatory presentation of cardiac safety assessments conducted during their clinical trial programs.
Professor Turner's research has informed countless clinical studies. His most recent book, Integrated Cardiac Safety: Assessment Methodologies for Noncardiac Drugs in Discovery, Development and Postmarketing Surveillance (John Wiley & Sons, 2009), provides a first-of-its-kind comprehensive overview to the broad range of cardiac safety testing modalities. Representing the Cardiocore delegation, Professor Turner presented Integrated Cardiac Safety to pharmaceutical executives gathered last week at the Next Generation Pharmaceutical Summit in Westlake Village, CA.
Former Food and Drug Administration Associate Commissioner, Peter Pitts, PhD, has observed that Professor Turner's work, "returns us to the right path, the Critical Path, brightly lit by practical advice and sound science." Additionally, Peter Siegl, PhD, of Siegl Pharma Consulting, describes Integrated Cardiac Safety as, "An invaluable source of information for basic scientists, clinical investigators, physicians and regulators currently wrestling with the diverse challenges of cardiac safety."
With Professor Turner's expertise, Cardiocore enhances its value-adding educational services for biopharmaceutical clients. "Dr. Turner has developed illuminating and informative seminars in translational medicine and clinical pharmacology," explained Cardiocore Chief Medical Officer, Lawrence Satin, MD, FACC. Noting Turner's success as an academician and his numerous publications in first-tier, peer-reviewed journals, Dr. Satin added, "No one in the industry is better skilled at delivering cardiac safety tutorials for broad based pharmaceutical development teams."
In his role as Cardiocore Senior Scientist, Professor Turner will work closely with Dr. Satin and other distinguished members of Cardiocore's scientific leadership team including Vice President of Operations, Polina Voloshko, MD and Senior Scientists Daniel Goodman, MD and Nelson Schiller, MD, FACC.
"I am proud to join this prestigious team," commented Dr. Turner. "Cardiocore has always applied its vast scientific experience to help sponsors advance their development programs rapidly and efficiently. I look forward to helping extend those benefits to more research professionals around the world."
Complementing his duties at Cardiocore, Dr. Turner serves as a Visiting Fellow at the Center for Medicine in the Public Interest and an active member of the Institute of Clinical Research, the Science Council, and the Cardiac Safety Research Consortium. Born and raised in the United Kingdom, he obtained undergraduate and graduate degrees from the University of Sheffield and Sheffield Hallam University, and a doctorate of philosophy with a specialty in Cardiovascular Behavioral Medicine from the University of Birmingham.
About Cardiocore: Cardiocore has provided superior centralized cardiac testing services to the pharmaceutical industry for 17 years. Services include centralized electrocardiography (ECG), Holter monitoring, echocardiography (ECHO), multigated acquisition scans (MUGA), protocol development and statistical analysis. The company is experienced in cardiac safety and efficacy testing in Phase I-IV and Thorough QT clinical trials. These services are supported by the company's advanced data management system featuring the proprietary HolterGateway™ and CardioPortal™. Cardiocore's U.S. headquarters is located in Bethesda, Maryland, its West Coast office is located in San Francisco, California, and its European subsidiary, Cardiocore Limited, is located in London, England. http://www.cardiocore.com.